Actively Recruiting
Velsipity Tablets 2 mg Special Investigation on Long-Term Use in Patients With Ulcerative Colitis
Led by Pfizer · Updated on 2026-05-18
553
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to assess the safety and effectiveness of Velsipity Tablets 2 mg when used long-term, up to 52 weeks, in patients with moderate to severe ulcerative colitis. The study focuses on patients receiving treatment with Velsipity in real-world medical practice. Sponsored by Pfizer, this observational study monitors how the medication performs outside of controlled clinical trials, gathering important safety and symptom remission data. Participants in this study are patients taking Velsipity tablets as prescribed by their doctors. The study observes their treatment over a period of up to one year without assigning any new treatments or placebos. Data collection includes tracking any serious infections, adverse reactions, and symptom improvements during the treatment period. Throughout the study, participants will be monitored for safety outcomes, including the incidence of serious infections and adverse drug reactions, for up to 52 weeks. Researchers will also evaluate the percentage of participants achieving symptomatic remission at 12 weeks and again at 52 weeks. All data will be gathered under actual medical practice conditions, and participants will continue their usual care with their healthcare providers during the study.
CONDITIONS
Brief Title
An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with moderate to severe ulcerative colitis who started treatment with Velsipity for the first time after the study start date
- Patients who understand the study and consent to sharing their collected information with third parties and for other uses
You will not qualify if you...
- Patients who have participated in a clinical study of Velsipity in the past
- Patients who have previously participated in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 52 weeks
Participants take Velsipity tablets as prescribed in real world practice.
Visits occur during treatment as per real world practice
Duration - Up to 52 weeks
Participants are monitored for safety and effectiveness of Velsipity over time.
Visits for safety and symptom monitoring up to 52 weeks
Trial Site Locations
Total: 1 location
1
Pfizer
Tokyo, Japan
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here